Rapsyn congenital myasthenic syndrome worsened by fluoxetine

Amy Visser, Ruple S. Laughlin, William J. Litchy, Eduardo E. Benarroch, Margherita Milone

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: Fluoxetine is a selective serotonin reuptake inhibitor and long-lived open channel blocker of the acetylcholine receptor, often used in the treatment of slow-channel congenital myasthenic syndromes (CMS). Methods: We report a 42-year-old woman who had a history of episodic limb weakness that worsened after initiation of fluoxetine for treatment of depression. Genetic testing for CMS revealed a homozygous pathogenic mutation in the rapsyn (RAPSN) gene (p.Asn88Lys). Electrodiagnostic testing was performed before and 1 month after discontinuation of fluoxetine. Results: The 2 Hz repetitive nerve stimulation of the fibular and spinal accessory nerves showed a baseline decrement of 36% and 14%, respectively. One month after discontinuing fluoxetine, the spinal accessory nerve decrement was no longer present, and the decrement in the fibular nerve was improved at 17%. Conclusions: This case demonstrates worsening of both clinical and electrophysiologic findings in a patient with CMS secondary to a RAPSN mutation treated with fluoxetine. Muscle Nerve 55: 131–135, 2017.

Original languageEnglish (US)
Pages (from-to)131-135
Number of pages5
JournalMuscle and Nerve
Volume55
Issue number1
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Congenital Myasthenic Syndromes
Fluoxetine
Accessory Nerve
Peroneal Nerve
Mutation
Serotonin Uptake Inhibitors
Genetic Testing
Cholinergic Receptors
Extremities
peripheral membrane protein 43K
Muscles
Therapeutics
Genes

Keywords

  • congenital myasthenic syndrome
  • fluoxetine
  • myasthenia
  • RAPSN, rapsyn gene
  • repetitive nerve stimulation
  • RNS

ASJC Scopus subject areas

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)

Cite this

Visser, A., Laughlin, R. S., Litchy, W. J., Benarroch, E. E., & Milone, M. (2017). Rapsyn congenital myasthenic syndrome worsened by fluoxetine. Muscle and Nerve, 55(1), 131-135. https://doi.org/10.1002/mus.25244

Rapsyn congenital myasthenic syndrome worsened by fluoxetine. / Visser, Amy; Laughlin, Ruple S.; Litchy, William J.; Benarroch, Eduardo E.; Milone, Margherita.

In: Muscle and Nerve, Vol. 55, No. 1, 01.01.2017, p. 131-135.

Research output: Contribution to journalArticle

Visser, A, Laughlin, RS, Litchy, WJ, Benarroch, EE & Milone, M 2017, 'Rapsyn congenital myasthenic syndrome worsened by fluoxetine', Muscle and Nerve, vol. 55, no. 1, pp. 131-135. https://doi.org/10.1002/mus.25244
Visser A, Laughlin RS, Litchy WJ, Benarroch EE, Milone M. Rapsyn congenital myasthenic syndrome worsened by fluoxetine. Muscle and Nerve. 2017 Jan 1;55(1):131-135. https://doi.org/10.1002/mus.25244
Visser, Amy ; Laughlin, Ruple S. ; Litchy, William J. ; Benarroch, Eduardo E. ; Milone, Margherita. / Rapsyn congenital myasthenic syndrome worsened by fluoxetine. In: Muscle and Nerve. 2017 ; Vol. 55, No. 1. pp. 131-135.
@article{c90e88d1eb4040d680bfeba2e5945fff,
title = "Rapsyn congenital myasthenic syndrome worsened by fluoxetine",
abstract = "Introduction: Fluoxetine is a selective serotonin reuptake inhibitor and long-lived open channel blocker of the acetylcholine receptor, often used in the treatment of slow-channel congenital myasthenic syndromes (CMS). Methods: We report a 42-year-old woman who had a history of episodic limb weakness that worsened after initiation of fluoxetine for treatment of depression. Genetic testing for CMS revealed a homozygous pathogenic mutation in the rapsyn (RAPSN) gene (p.Asn88Lys). Electrodiagnostic testing was performed before and 1 month after discontinuation of fluoxetine. Results: The 2 Hz repetitive nerve stimulation of the fibular and spinal accessory nerves showed a baseline decrement of 36{\%} and 14{\%}, respectively. One month after discontinuing fluoxetine, the spinal accessory nerve decrement was no longer present, and the decrement in the fibular nerve was improved at 17{\%}. Conclusions: This case demonstrates worsening of both clinical and electrophysiologic findings in a patient with CMS secondary to a RAPSN mutation treated with fluoxetine. Muscle Nerve 55: 131–135, 2017.",
keywords = "congenital myasthenic syndrome, fluoxetine, myasthenia, RAPSN, rapsyn gene, repetitive nerve stimulation, RNS",
author = "Amy Visser and Laughlin, {Ruple S.} and Litchy, {William J.} and Benarroch, {Eduardo E.} and Margherita Milone",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/mus.25244",
language = "English (US)",
volume = "55",
pages = "131--135",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Rapsyn congenital myasthenic syndrome worsened by fluoxetine

AU - Visser, Amy

AU - Laughlin, Ruple S.

AU - Litchy, William J.

AU - Benarroch, Eduardo E.

AU - Milone, Margherita

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Introduction: Fluoxetine is a selective serotonin reuptake inhibitor and long-lived open channel blocker of the acetylcholine receptor, often used in the treatment of slow-channel congenital myasthenic syndromes (CMS). Methods: We report a 42-year-old woman who had a history of episodic limb weakness that worsened after initiation of fluoxetine for treatment of depression. Genetic testing for CMS revealed a homozygous pathogenic mutation in the rapsyn (RAPSN) gene (p.Asn88Lys). Electrodiagnostic testing was performed before and 1 month after discontinuation of fluoxetine. Results: The 2 Hz repetitive nerve stimulation of the fibular and spinal accessory nerves showed a baseline decrement of 36% and 14%, respectively. One month after discontinuing fluoxetine, the spinal accessory nerve decrement was no longer present, and the decrement in the fibular nerve was improved at 17%. Conclusions: This case demonstrates worsening of both clinical and electrophysiologic findings in a patient with CMS secondary to a RAPSN mutation treated with fluoxetine. Muscle Nerve 55: 131–135, 2017.

AB - Introduction: Fluoxetine is a selective serotonin reuptake inhibitor and long-lived open channel blocker of the acetylcholine receptor, often used in the treatment of slow-channel congenital myasthenic syndromes (CMS). Methods: We report a 42-year-old woman who had a history of episodic limb weakness that worsened after initiation of fluoxetine for treatment of depression. Genetic testing for CMS revealed a homozygous pathogenic mutation in the rapsyn (RAPSN) gene (p.Asn88Lys). Electrodiagnostic testing was performed before and 1 month after discontinuation of fluoxetine. Results: The 2 Hz repetitive nerve stimulation of the fibular and spinal accessory nerves showed a baseline decrement of 36% and 14%, respectively. One month after discontinuing fluoxetine, the spinal accessory nerve decrement was no longer present, and the decrement in the fibular nerve was improved at 17%. Conclusions: This case demonstrates worsening of both clinical and electrophysiologic findings in a patient with CMS secondary to a RAPSN mutation treated with fluoxetine. Muscle Nerve 55: 131–135, 2017.

KW - congenital myasthenic syndrome

KW - fluoxetine

KW - myasthenia

KW - RAPSN, rapsyn gene

KW - repetitive nerve stimulation

KW - RNS

UR - http://www.scopus.com/inward/record.url?scp=84992513260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992513260&partnerID=8YFLogxK

U2 - 10.1002/mus.25244

DO - 10.1002/mus.25244

M3 - Article

C2 - 27397848

AN - SCOPUS:84992513260

VL - 55

SP - 131

EP - 135

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 1

ER -